about
Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations.What preclinical data are needed to justify once-daily therapy?Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis.Once-daily aminoglycosides in the treatment of gram-positive endocarditis.Minimisation of aminoglycoside toxicity in patients with cystic fibrosisImpact of antimicrobial agents and chemotherapy from 1972 to 1998.Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicityDetermination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionA suggested approach to once-daily aminoglycoside dosing.Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice dailyDifferent patterns of bacterial DNA synthesis during postantibiotic effectEffects of fasting on temporal variations in nephrotoxicity of gentamicin in rats.Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.Once-daily gentamicin therapy for experimental Escherichia coli meningitis.Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modalityVersatility of aminoglycosides and prospects for their future.Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.Single daily dosing of gentamicin: pharmacokinetic comparison of two dosing methodologies for postpartum endometritisThe pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.Single-dose antibiotic therapy: what has the past taught us?Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis.Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.Effect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli.Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditisComparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.The role of preoperative antibiotics in the prevention of wound infection after day case surgery for inguinal hernia in children in Ile Ife, Nigeria.Once-daily gentamicin dosing in pediatric patients without cystic fibrosis.Aminoglycoside use in renal failure.Controversies in the management of Mycobacterium avium complex infection in AIDS patients.Infection caused by Mycobacterium tuberculosis.Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial.Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis modelExperience with a once-daily aminoglycoside program administered to 2,184 adult patients.Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosingKill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.
P2860
Q30833424-17840DC3-F110-4C5C-8B89-4C980D2B8131Q30899947-BA967DA5-2125-49C0-A93E-E698623BBEFBQ30901078-A7FBEEF5-37A2-489B-ADDC-BA4485654C71Q33659372-AF5E9D71-CC02-4DCA-892D-F9F0CB56128FQ33775991-FCADE682-B0CC-43A3-8830-1174FC45E0BEQ33970709-3CF65F34-6E3E-474E-ACBD-75AC9E441559Q33977062-F1C34B2C-E365-48F5-A5AE-E77B03E8FCABQ34141627-44A11280-7AB0-47FA-8847-F3D2030059FEQ34347273-6E0904CA-3E4F-4FC3-916C-50A9CCF774BCQ35111295-279E5F0D-6025-43E6-AB72-EF31719F72DDQ35115294-51FEDC47-3DCE-48E2-943D-12FEEDB1D05EQ35123082-4710231C-736F-443B-A8D9-6B90AF4AD4FFQ35123348-41A3EE9D-0615-491D-8D0D-93BA1D276DFEQ35126962-CEB63ACA-4AA7-4BE7-8D1B-F5D11D8D1C5BQ35130895-BEAAD7DA-E534-4775-B81D-B4BB9FF836F0Q35136143-3E228702-EBDE-4449-B356-BC1EC1CA9211Q35139187-AB559C7D-597A-4FD9-90EC-0424376F9180Q35176271-6021CA5E-1DDF-4B07-AA73-A293EC67EA08Q35259780-3C55F248-E18E-406C-9A72-636D9EC89339Q35615212-4EE2ED07-D5BD-496E-A089-E1A7A327C5D1Q35615484-10183C0C-13DD-4CC2-BE2C-F85F847D0CD9Q35661686-BE86FBE4-A014-415D-8706-CAC9D14BD84BQ35808378-3DAD7EEE-7C93-4EC3-A77A-7CA00D99ACDBQ35819639-E5919F90-C563-40F1-BBD7-FDCF9699BE39Q35836760-39B6A866-27BB-4223-9585-7B52C8EB0955Q35845654-592283C6-C2EB-40DE-AADD-BEDC76ECC7A4Q35885240-213029D4-D977-41D6-9C35-0E7799D361A4Q36053937-D7695C5D-3870-4FAC-A899-D2ABC1F6F409Q36099490-E3AF2211-E682-4C98-B2BF-A91E6B231F14Q37251770-1A11E212-B18A-46D3-AC58-694C01875FD3Q37697773-8D2F1B9A-AD67-457E-82E3-3C14608106FCQ37808935-F11669B3-FCA6-4825-B04F-3D860F75F067Q38566706-42E55443-9D25-4AB3-9747-6A59D97BB026Q38569137-73D978B0-84BC-4D86-99E0-E75682A03A23Q39510044-4C11D54A-8605-4AF8-87B1-26B968661963Q39651068-80CD8866-92DE-49FF-9366-F8F465178649Q39779327-C896E215-6DA2-48A6-AE92-F2307974215DQ39782178-AA76D066-E616-4863-A7E6-D6DB480FBAFDQ39865745-0D029030-9392-42BE-AC0B-8DA0DB5624A7Q39881843-3AE922C3-8014-47DC-B284-244367A8FD7E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Once-daily aminoglycoside therapy
@en
Once-daily aminoglycoside therapy.
@nl
type
label
Once-daily aminoglycoside therapy
@en
Once-daily aminoglycoside therapy.
@nl
prefLabel
Once-daily aminoglycoside therapy
@en
Once-daily aminoglycoside therapy.
@nl
P2860
P356
P1476
Once-daily aminoglycoside therapy
@en
P2093
Gilbert DN
P2860
P304
P356
10.1128/AAC.35.3.399
P407
P577
1991-03-01T00:00:00Z